Skip to content
1383-SGLT2i Improves Diastolic Dysfunction in hiPSC Heart episode artwork

Aug 4, 2026 22 min

1383-SGLT2i Improves Diastolic Dysfunction in hiPSC Heart

from Paper Talk

Researchers have successfully developed a human engineered heart tissue model to study diastolic dysfunction in heart failure with preserved ejection fraction (HFpEF). By utilizing human induced pluripotent stem cells, the study effectively replicated key pathological traits, such as impaired relaxation and fibrosis, without the need for animal testing. The findings highlight that SGLT2 inhibitors provide significant therapeutic benefits by reducing inflammation and restoring critical cellular signaling pathways. This recovery is largely driven by the improvement of endothelial cell function and the stabilization of sodium and calcium levels. Ultimately, this sophisticated in vitro system offers a reproducible platform for discovering new treatments and understanding the complex mechanisms of human heart disease. References: Tani H, Haga K, Moriwaki T, et al. Human iPSC-derived engineered heart tissue model of diastolic dysfunction in heart failure with preserved ejection fraction[J]. Cell Stem Cell, 2026. 前往小宇宙评论区与主播互动

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

1383-SGLT2i Improves Diastolic Dysfunction in hiPSC Heart

0:00 22:26

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Paper Talk?

This episode is 22 minutes long.

When was this Paper Talk episode published?

This episode was published on August 4, 2026.

Can I download this Paper Talk episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.